Dr. Luke Whitesell is a co-founder of, and consultant to, Bright Angel Therapeutics and an oncologist and molecular pharmacologist within the Department of Molecular Genetics at the University of Toronto. Board-certified in pediatric oncology (inactive status), he has over two decades prior experience in cooperative group clinical trials and the clinical management of children with invasive fungal infections, especially in the bone marrow transplant setting. He currently helps guide translational drug discovery and development efforts within the Cowen laboratory. His research has led to publication of well over 100 peer-reviewed manuscripts, 3 issued patents and 2 pending applications. Prior to joining the Cowen lab in 2017, Luke was a principal investigator at the Whitehead Institute for over a dozen years where he led or helped lead multiple high throughput screening and pre-clinical development efforts performed in conjunction with the Broad Institute, MIT Koch Institute for Integrative Cancer Research, Harvard ICCB and NIH NCATS program.

• 

  Co-Founder in Bright Angel Therapeutics

  Bright Angel Therapeutics is Startup in Toronto

• 

  Advisor in Bright Angel Therapeutics

  Bright Angel Therapeutics is Startup in Toronto